Overall survival results of the Phase III MONALEESA‑3 trial of postmenopausal patients with hormone receptor-positive human-epidermal growth factor-2-negative advanced breast cancer treated with fulvestrant plus/minus ribociclib - Slamon, D; Neven, P; Chia, S (Ann Oncol, 2019)
et al.